Apixaban 5 MG
Sponsors
Portola Pharmaceuticals, Hopital Lariboisière, University Hospital, Lille, Assistance Publique - Hôpitaux de Paris, Artivion Inc.
Conditions
Aortic Valve DiseaseAortic Valve FailureAortic Valve StenosisAtrial FibrillationBleedingCancer-associated ThrombosisCoagulation DisorderHeavy Menstrual Bleeding
Phase 1
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
CompletedNCT03083704
Start: 2017-02-26End: 2017-09-28Updated: 2023-08-08
A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
CompletedNCT04278729
Start: 2021-04-14End: 2023-09-22Updated: 2023-09-26
Phase 3
Avoiding Anticoagulation After IntraCerebral Haemorrhage
RecruitingNCT03243175
Start: 2019-01-17End: 2028-12-31Target: 300Updated: 2025-02-06
API-CAT STUDY for APIxaban Cancer Associated Thrombosis
CompletedNCT03692065
Start: 2018-10-11End: 2024-10-20Updated: 2025-02-06
PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban
TerminatedNCT04142658
Start: 2020-05-01End: 2022-12-12Updated: 2024-03-20
Unknown Phase
Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban
TerminatedNCT03136510
Start: 2016-09-30End: 2019-03-31Updated: 2024-07-26
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
CompletedNCT04477837
Start: 2020-10-15End: 2024-06-15Updated: 2024-08-21